This story has been updated to include information about Ayvakit's wholesale acquisition cost.
NEW YORK – The US Food and Drug Administration has approved avapritinib (Blueprint Medicines' Ayvakit) for unresectable or metastatic gastrointestinal stromal tumors (GIST) harboring a PDGFRA exon 18 mutation.